Table 2 Clinical characteristics of the patients with and without contrast-induced nephropathy

Age (years), mean (SD)

58.4 ± 8.4

64.5 ± 14.7

P<0.001

Gender (female), n(%)

17 (43.6)

65 (32.5)

0.13

Body mass index (Kg/m²)

24.6 ± 2.7

24.7 ± 2.4

0.85

Diabetes Mellitus, n(%)

11 (28.2)

29 (14.5)

0.04

Hypertension, n(%)

21 (53.8)

40 (20.0)

P<0.001

Stroke history, n(%)

5 (12.8)

3 (1.5)

0.004

Current smoker, n(%)

7 (17.9)

63 (31.5)

0.06

Previous MI, n(%)

15 (38.5)

50 (25.0)

0.11

Systolic blood pressure (mmHg)

120.6 ± 12.6

126.5 ± 13.8

0.009

Diastolic blood pressure (mmHg)

74.5 ± 9.2

72.1 ± 8.1

P<0.001

Pulse pressure (mmHg)

54.4 ± 12.1

46.1 ± 9.7

P<0.001

LVEF

0.47 ± 0.07

0.44 ± 0.06

0.02

NYHA 2–3 on admision

7 (17.9)

30 (15.0)

0.40

Total Cholesterol (mg/dl)

4.4 ± 0.7

4.3 ± 1.1

0.33

LDL-C (mmol/L)

2.8 ± 0.5

2.5 ± 0.6

0.007

HDL-C (mmol/L)

1.0 ± 0.2

1.1 ± 0.3

0.09

Triglyceride (mmol/L)

1.4 ± 0.6

1.5 ± 1.3

0.35

Fasting Glucose (mmol/L)

5.4 ± 0.7

5.8 ± 1.3

0.004

Baseline eGFR (ml/min/1.73m²)

94.6 ± 17.6

92.7 ± 20.3

0.53

Baseline Creatinine (μmol/l)

69.2 ± 18.0

65.3 ± 15.6

0.21

Uric acid (μmol/l)

355.4 ± 72.4

326.9 ± 69.4

0.02

Total amount of conrrast (ml)

299.2 ± 105.2

227.1 ± 98.3

P<0.001

The retrograde approach, n(%)

6 (15.4)

51 (25.5)

0.12

Transradial + transfemoral approach, n(%)

12 (30.8)

68 (34.0)

0.85

Procedural duration (min)

91.0 ± 50.0

120.9 ± 48.4

P<0.001

IABP, n(%)

3 (7.7)

14 (7.0)

0.75

IVUS, n(%)

4 (10.3)

14 (7.0)

0.51

Stent number

2.2 ± 0.9

2.2 ± 0.6

0.96

Glycoprotein IIb/IIIa receptor inhibitor, n(%)

18 (46.2)

31 (15.5)

P<0.001

CHA2DS2-VASc Score

3.1 ± 1.2

2.1 ± 1.1

P<0.001